Business Context and Reporting Period
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing peptide-based investigational medicines for hematology, blood disorders, inflammatory diseases and immunomodulatory conditions. This unaudited Form 10-Q covers the three and nine months ended September 30, 2021, filed November 3, 2021.
Key programs included rusfertide (PTG-300), PN-943, and Janssen-collaborated IL-23 receptor candidates PN-232 and PN-235. The company had no approved products and no product sales revenue.
Financial Highlights
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| License and collaboration revenue | $10.3 million | $13.1 million | $18.7 million | $23.0 million |
| Research and development expense | $37.0 million | $16.0 million | $87.6 million | $55.0 million |
| General and administrative expense | $7.3 million | $4.9 million | $19.9 million | $13.6 million |
| Net loss | $33.8 million | $7.8 million | $88.6 million | $47.3 million |
| Net loss per share | $0.70 | $0.21 | $1.94 | $1.45 |
Q3 operating loss was $33.9 million, equivalent to an operating margin of approximately negative 330% of revenue. Nine-month operating loss was $88.8 million. Stock-based compensation was $4.8 million in Q3 and $11.4 million for the nine-month period.
- Cash, cash equivalents and marketable securities totaled $352.5 million at September 30, 2021, compared with $307.8 million at December 31, 2020.
- Cash used in operating activities was $80.9 million for the nine months, versus $53.6 million in the prior-year period.
- Cash used in investing activities was $43.7 million, primarily reflecting net purchases of marketable securities.
- Cash provided by financing activities was $127.8 million, including $124.0 million of net proceeds from a June 2021 public offering.
- Total assets were $373.2 million and stockholders’ equity was $329.7 million at September 30, 2021.
- The company had no outstanding debt after releasing all obligations under its term loan facility in September 2021. Operating lease liabilities totaled $6.3 million.
Material Changes Versus the Prior Comparable Period
- Revenue declined 22% in Q3 and 18% for the nine months, despite an $8.0 million cumulative catch-up revenue adjustment related to the amended Janssen agreement.
- Research and development expense increased 131% in Q3 and 59% for the nine months. The principal drivers were higher rusfertide and PN-943 clinical costs, initial PN-232 and PN-235 development, increased preclinical research, and a $4.0 million Zealand-related milestone payment obligation.
- General and administrative expense increased 48% in Q3 and 46% for the nine months, primarily due to higher personnel, consulting, market research and recruiting costs.
- The company issued approximately 3.5 million shares in its June 2021 public offering and ended the quarter with 47.7 million shares outstanding, versus 43.7 million at December 31, 2020.
- The July 2021 amended and restated Janssen agreement reduced the company’s future development obligations, with Janssen assuming responsibility for most future development expenses outside specified PTG-200, PN-232 and PN-235 activities.
- In August 2021, the company resolved its arbitration with Zealand. It paid $2.5 million immediately, must pay an additional $1.5 million in August 2022, and may owe up to $2.75 million in additional future rusfertide development milestones.
- The company expanded its Newark facility by approximately 15,000 square feet, recording an additional right-of-use asset and lease liability of approximately $1.4 million.
Guidance, Outlook, Risks and Unusual Items
- Management stated that existing cash, cash equivalents and marketable securities should fund anticipated operating and capital requirements for at least 12 months from the filing date, but expects to require substantial additional financing for continued development and potential commercialization.
- Management expects continued operating losses and increasing research and development expenses as programs advance. The filing provides no profitability guidance.
- Rusfertide clinical studies were placed on FDA clinical hold in September 2021 after tumor findings in a 26-week rasH2 transgenic mouse study. The hold was removed on October 8, 2021, after the company submitted a Complete Response. The company expected dosing to resume in the fourth quarter of 2021.
- The animal findings prompted re-examination of four cancer cases among more than 160 rusfertide trial participants; two cases were reclassified as possibly related to treatment. The filing states that no additional cancer cases or other unexpected safety signals were identified.
- The company expected to initiate a global Phase 3 rusfertide study in polycythemia vera in the first quarter of 2022, subject to regulatory and development conditions.
- PN-235 Phase 1 was completed, with a Phase 2 psoriasis study anticipated in early 2022. PN-232 Phase 1 completion was expected by mid-2022, and additional inflammatory bowel disease development was expected to begin in 2022.
- The company became eligible in October 2021 for a $7.5 million Janssen milestone upon completion of PN-235 Phase 1 data collection. It also remained eligible for approximately $900 million of development-related milestones, in addition to $87.5 million already earned, subject to achievement of applicable conditions.
- Material risks include clinical failure or delays, regulatory holds, safety findings, COVID-19-related trial and supply-chain disruptions, dependence on Janssen and other third parties, additional capital needs and potential equity dilution, manufacturing constraints, intellectual-property challenges and biotechnology-sector volatility.
Important Facts for Investors to Verify
- Confirm the status and duration of the FDA clinical hold removal, rusfertide dosing resumption, safety monitoring and subsequent clinical data.
- Verify achievement and cash collection of the $7.5 million Janssen milestone and the timing of future Phase 2-related milestones.
- Assess whether the $352.5 million liquidity balance remains sufficient under updated clinical, manufacturing and regulatory spending plans.
- Review the amended Janssen agreement for remaining cost-sharing obligations, termination provisions, milestone economics and royalty rights.
- Track future payments and milestone exposure under the Zealand settlement, including the $1.5 million 2022 payment and potential additional payments of up to $2.75 million.
- Evaluate dilution from outstanding options, warrants, restricted stock units and future equity offerings; the filing disclosed 9.4 million potentially dilutive securities excluded from loss-per-share calculations.